Complex prolactin crosstalk in breast cancer: New therapeutic implications
被引:42
作者:
Carver, Kristopher C.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA
Univ Wisconsin, Cellular & Mol Biol Program, Madison, WI 53706 USA
Univ Wisconsin, Biotechnol Training Program, Madison, WI 53706 USAUniv Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA
Carver, Kristopher C.
[1
,2
,3
]
Arendt, Lisa M.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA
Univ Wisconsin, Cellular & Mol Biol Program, Madison, WI 53706 USAUniv Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA
Arendt, Lisa M.
[1
,2
]
Schuler, Linda A.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA
Univ Wisconsin, Cellular & Mol Biol Program, Madison, WI 53706 USA
Univ Wisconsin, Biotechnol Training Program, Madison, WI 53706 USAUniv Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA
Schuler, Linda A.
[1
,2
,3
]
机构:
[1] Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA
[2] Univ Wisconsin, Cellular & Mol Biol Program, Madison, WI 53706 USA
[3] Univ Wisconsin, Biotechnol Training Program, Madison, WI 53706 USA
Prolactin;
Breast cancer;
Signaling crosstalk;
Targeted therapeutics;
ESTROGEN-RECEPTOR-ALPHA;
ACTIVATED PROTEIN-KINASE;
EPIDERMAL-GROWTH-FACTOR;
MAMMARY-GLAND DEVELOPMENT;
STAT 5A EXPRESSION;
PROGESTERONE-RECEPTOR;
ACQUIRED-RESISTANCE;
MOUSE MAMMARY;
SIGNAL TRANSDUCER;
EPITHELIAL-CELLS;
D O I:
10.1016/j.mce.2009.03.014
中图分类号:
Q2 [细胞生物学];
学科分类号:
071009 ;
090102 ;
摘要:
The contributions of prolactin (PRL) to breast cancer are becoming increasingly recognized. To better understand the role for PRL in this disease, its interactions with other oncogenic growth factors and hormones must be characterized. Here, we review our current understanding of PRL crosstalk with other mammary oncogenic factors, including estrogen, epidermal growth factor (EGF) family members, and insulin-like growth factor-I (IGF-I). The ability of PRL to potentiate the actions of these targets of highly successful endocrine and molecular therapies suggests that PRL and/or its receptor (PRLR) may be an attractive therapeutic target(s). We discuss the potential benefit of PRL/PRLR-targeted therapy in combination with established therapies and implications for de novo and acquired resistance to treatment. (C) 2009 Elsevier Ireland Ltd. All rights reserved.